Emile Nuwaysir, Ph.D., CEO 

Oct. 11 | 4:00pm | Rentschler ATMP Ballroom 

Boston, MA 


Ensoma believes the future of medicine lies within us. The company is poised to create a new therapeutic category addressing diseases that impact millions around the globe, such as cancer, autoimmunity, and genetic disease. The Engenious™ platform can uniquely address these disorders by leveraging world-class technologies for in vivo delivery and genome engineering. The ability to target and reprogram both immune cells and self-renewing hematopoietic stem cells will create multicellular and multigenic medicines that solve potency and durability challenges limiting current approaches. Ensoma also has the potential to leapfrog therapies in well validated indications such as hemoglobinopathies and dramatically expand patient eligibility through its portable in vivo solutions. Ensoma is supported by top-tier investors, strategic partners and a passionate team committed to a bold, global vision for genomic medicine.


By using this website you agree to accept our Privacy Policy and Terms & Conditions